PDS Biotech Q3 net loss $9.0M; Phase 2 mOS 39.3 months; seeks accelerated approval

PDS Biotechnology Corp

2025-Q3 EPS reported -$0.60 vs consensus -$0.22 ▼ miss (-175.7%)

Q3 net loss $9.0M ($0.19/share) vs $10.7M ($0.29) YoY; R&D expenses down to $4.6M.
Cash $26.2M at Sep 30, 2025 vs $41.7M Dec 2024; raised ~$5.3M on Nov 12 stock/warrant sale.
VERSATILE-002 Phase 2 complete: mOS 39.3 months, PFS 6.3 months in CPS≥1 HNSCC patients.
Plans to amend VERSATILE-003 Phase 3 to seek accelerated approval with PFS as surrogate endpoint.
Colorectal cancer cohort of PDS01ADC met Stage 2 expansion criteria (≥6 of 9 objective responses).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.